Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Study:

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Rationale:

n/a

Purpose:

In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with refractory chronic lymphocytic leukemia.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Lymphocytic Leukemia, Chronic Drug: MGCD0103 Phase 2

Verified by MethylGene Inc. October, 2013

Sponsored by: MethylGene Inc.
Information provided by: MethylGene Inc.
ClinicalTrials.gov identifier: NCT00431873

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic/Chronic Leukemia/Multiple Myeloma Program
Cleveland, Ohio 44195
United States

Gregory Reid, MSc, MBA., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site